The 12-Month DivergenceSame patient. Same drug. Different outcome.
Month 0 — EnrollmentMonth 0Month 12 — Outcome
Standard Clinic
Prescription + "eat well, exercise"
Scale Weight
215lbs
Lean Mass
145lbs
HRV
41ms
Visceral Fat
18idx
No biometric monitoring · No algorithm · No intervention triggers
Metabolic Guard Rail
Continuous monitoring + Outlaw Index
OI: 12
Scale Weight
215lbs
Lean Mass
145lbs
HRV
41ms
Visceral Fat
18idx
Lean mass: +0 lbs gained
Oura Ring · Squegg · CGM · Renpho · Outlaw Index · Physician alerts
M0055110165220
  • Standard Clinic
  • Guard Rail
Guard Rail Intervention Timeline— Standard clinic has none
M3
D1 Autonomic
Added Mg Glycinate + Taurine. Reduced cardio intensity. Adjusted injection-day rest protocol.
✓ HRV recovered to baseline by M4.
M6
D2 Sarcopenia
Increased protein target to 1.6g/kg. Added creatine 5g/day. Shifted exercise to 3× resistance/week.
✓ Grip strength stabilized. Lean mass held.
M9
D3 Metabolic
Scheduled lab draw. rT3/FT3 ratio optimal. IGF-1 in range. Fasting insulin declining.
✓ No intervention needed. Dose escalation approved.

Data modeled from published GLP-1 clinical trial outcomes (STEP, SURMOUNT, SUSTAIN trial series). Lean mass loss of 25–40% of total weight lost is consistent with published literature. HRV decline under caloric restriction and sympathetic activation is well-documented. Individual results vary. This visualization is for educational and investor illustration purposes.